Keytruda in new lymphoma use leads latest CHMP decisions
blood cancer, Bristol-Myers Squibb, cancer, cancer immunotherapy, CHMP decisisons 2017, Merck & Co, Novo Nordisk
0 Comment
MSD keeps pressure on BMS with EU classical Hodgkin lymphoma indication.